About 60% of patients say they feel anxious the first time they self-inject at home. That apprehension is not irrational. One study found 76% of treatment-naïve patients reported anxiety simply when shown a 12mm syringe needle, before any clinical event had occurred [external 3]. The first dose is a moment of high emotional load, low confidence, and zero supervision.
And yet in many launch kits, the self-administration video is still produced last, after the leaflet, the website, and the HCP detail aid. That order reflects an old assumption: that the video is a marketing asset. It isn't. It is the piece of communication a patient actually uses, in their kitchen, holding a device, with no nurse in the room.
As Promedia's self-administration briefing puts it, the gap in this category is rarely in the science. The gap is in the materials, the training, and the moment-of-truth support [1]. Fixing that gap is what a serious self-administration video pharma program is for.
The clinical stakes are concrete. In insulin therapy, one study reported lipohypertrophy prevalence of 42.9% among treated patients, strongly associated with injection-technique errors, and lipohypertrophy itself was linked to a 2.7-times higher risk of severe hypoglycemia [3]. A "simple" technique issue, repeated daily, becomes a clinical and economic problem. Medication nonadherence more broadly is associated with up to 25% of US hospitalizations each year, and roughly half of patients on chronic medications do not stay on plan [external 4].
A biologic injection instructional video does three things at once that a written PIL cannot:
That is patient safety work. It happens to live on a screen.
Regulators already treat training as part of the product, not as promotion. FDA frames patient training and labeling as part of a drug-device product's user interface, and expects human factors evaluation showing that representative users can perform critical tasks and understand the instructions needed for safe use. In the EU, EMA guidance on drug-device combinations references MDR Article 117 and requires evidence that the device portion meets relevant general safety and performance requirements [2]. Labels for self-administered biologics commonly require "proper training" for patients and caregivers, including aseptic technique and correct device use [2].
That shapes how a compliant auto-injector patient education video gets built:
This is also where Med-Reg-Legal review needs to come in early, not at the end. Reshoots to fix a non-compliant gesture or an off-label phrase are expensive and slow.
The drivers of nonadherence in self-injected biologics are not mainly clinical. They are emotional and procedural: fear of incorrect technique, fear of needles, fear of side effects, low self-confidence [external 1]. A rheumatoid arthritis preference survey found that anxiety and hurdles related to self-injection were directly associated with patients preferring in-hospital administration over home use [3]. Patients who feel unsure opt out.
Step-by-step training tools and electromechanical device guidance help new self-injectors achieve correct technique and build confidence, reducing both anxiety and drug wastage [external 2]. Video carries this further because it can be rewatched. The UCB script invites exactly that behavior: "Please revisit this video if you need a reminder of how to self-inject" [4]. The patient is given permission to need a second look, which lowers the threshold for using the tool at all.
Inside a broader pharma patient support program, video also anchors the other touchpoints. Just-in-time messages, refill reminders, and educational follow-ups all work better when they point back to a single, trusted demonstration the patient has already seen [5]. The video becomes the reference object the rest of the program orbits around.
A strong home injection training material covers the full arc of the first dose, not just the injection itself. In practice, that means:
Visual choices matter. Promedia's adherence work with AbbVie stresses straightforward language paired with compelling visual aids to support understanding, especially for chronic-disease patients who need to internalize a daily or weekly routine [5]. Close-ups, real hands, real devices, and unhurried pacing do more for comprehension than stylized graphics.
Localization is the final, often underestimated layer. A Swiss German patient and a Belgian French patient need the same clinical accuracy in their own language, with the same voice-over warmth. Treating localization as a translation task rather than a re-recording often breaks the calm, instructional tone the video needs.
It is an instructional video designed to guide a patient or caregiver through the correct technique for administering an injectable therapy at home, typically a biologic, a GLP-1, or another subcutaneous treatment delivered by pre-filled syringe or auto-injector. It is built against the approved IFU and PIL, reviewed by Medical and Regulatory, and intended to function as a safety and training tool rather than a promotional asset.
Anxiety before a first injection is driven by uncertainty about technique, fear of needles, and low confidence [external 1]. A video lets the patient see the full procedure performed correctly, at a calm pace, before they attempt it themselves. They can rewatch it, share it with a caregiver, and use it as a reference at the moment of dosing. That predictability is what reduces apprehension.
Video as a specific format is not always mandated, but "proper training" for patients and caregivers on self-administered biologics is a common label requirement, and both FDA and EMA treat training materials as part of the drug-device user interface subject to human factors evaluation [2]. In practice, video is the most effective way to meet that training obligation for home use.
The PIL is a regulated text document. It is comprehensive and authoritative, but it asks the patient to read and interpret instructions while holding a device. A self-administration video translates the same content into demonstrated action, with timing, angle, and tone the patient can copy. The two are complementary. The video does not replace the PIL; it makes the PIL usable at the moment of the injection.
If adherence and correct administration are on your KPI list for a self-injected therapy, the video is not the last asset on the production schedule. It is among the first. Plan it alongside the IFU and the human factors work, not after the detail aid is signed off.
The practical move for most launch teams is to bring Medical, Regulatory, patient support, and the production partner into the same room at the script stage. Decisions made there determine whether the final video genuinely supports a nervous patient at their kitchen table, or whether it just exists on the brand website.
If it would help to talk through how a self-administration video pharma program fits alongside your launch materials and patient support program, Promedia works on these projects across therapy areas and languages.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
